Business Wire

LRN and Nordic Business Ethics Initiative to collaborate with the 2023 survey

Share

LRN Corporation, the leader in ethics and compliance solutions that enable organizations to inspire principled performance, today announces a collaboration with the Nordic Business Initiative (NBE) to deliver deeper insights into ethics and compliance (E&C) issues across the Nordic region.

LRN will be the exclusive provider of global E&C benchmarking data to NBE, which will give additional global context to the organization’s bi-annual ‘Nordic Ethics & Compliance Survey’ for the first time.

Nordic Ethics & Compliance Survey reports on trends in the state of ethics & compliance programs in the Nordic region. It analyzes data relating to internal Ethics & Compliance work in Nordic organisations. The survey responses are gathered from Denmark, Finland, Norway and Sweden.

LRN is an authoritative voice on global E&C issues and will provide key data insights and benchmarking from its world-leading 2023 Program Effectiveness Report, as well as previously unpublished insights from its full data set. The report is based on responses from more than 1,850 E&C professionals at organizations across 26 industries and in 10 different countries – the largest and most comprehensive research of its kind.

In addition to providing this extra global perspective to the NBE survey, experts from LRN will also be taking part in an event series alongside prominent speakers from NBE and other leading regional ethics and compliance experts examining the survey findings and exploring key themes and topical issues. The event series will take place after the publication of the full NBE report in November.

“The Nordic Business Ethics Initiative is doing vital work in building awareness of ethics and compliance across the Nordic region, and its research is a critical tool when it comes to understanding the state of play so that key issues can be addressed,” said Kevin Michielsen, CEO of LRN. “Our collaboration with NBE will give this important study a valuable extra dimension. For businesses across the Nordic region, including Nordic-based multi-national companies, it’s important to consider ethics and compliance issues against the global backdrop that takes account of geo-political developments, emerging challenges, and ongoing crises. The incorporation of our global data will help benchmark the performance of companies in the Nordics against their peers around the world and enable even better understanding the impact and efficacy of E&C programs.”

NBE co-founder Niina Ratsula added, “Being able to incorporate insights from LRN’s market-leading dataset into our 2023 Nordic Ethics & Compliance Survey report will give it, and our NBE members, even more value. By putting our findings around what’s happening in the Nordic region into the bigger, international picture, our research will have deeper meaning, so that organizations can see not just how the issues are developing around them, but what’s happening further afield too.”

Companies across the Nordic region are encouraged to participate in this year’s NBE survey by visiting: https://www.nordicbusinessethics.com/nordic-ethics-compliance-survey-2023/.

ENDS

Notes to Editors:

About LRN

LRN's mission and purpose is to inspire principled performance and help people around the world do the right thing. Since 1994, LRN has worked to propel organizations forward with the partnership, knowledge, and tools to build ethical culture. More than 2,800 companies and tens of millions of learners worldwide utilize LRN services and take LRN e-learning courses to help navigate complex regulatory environments and foster ethical, responsible, and inclusive cultures. In partnership with LRN, companies translate their values into concrete corporate practices and leadership behaviors that create sustainable competitive advantage. By acting upon shared values, companies and their people find the means to outbehave and outperform. Learn more at LRN.com and follow on Twitter, LinkedIn, and Facebook.

About the Nordic Business Ethics Initiative

The Nordic Business Ethics Initiative was created to build stronger and more responsible organizations. Its ambition is to promote responsible business conduct and support business leaders and professionals through sharing lessons learned, building best practices and facilitating dialogue and networking. The initiative consists of various activities, all aiming to raise awareness of what business ethics is and provide tools to create ethical, compliant workplaces.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Scott Addison, Charlotte Hole and Gabriel Oben, Infinite Global (for LRN Corporation)
LRN@infiniteglobal.com
Niina Ratsula, Co-Founder of Nordic Business Ethics Initiative, niina@nordicbusinessethics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

Illumynt Reports Q3 2025 Business Update17.10.2025 15:39:00 EEST | Press release

Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/

Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia17.10.2025 15:15:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia. In June 2025, Avanzanite entered into an exclusive agreement with Agios to commercialize and distribute PYRUKYND across the European Economic Area, the United Kingdom, and Switzerland. “The positive CHMP opinion for PYRUKYND represents a key step toward making th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye